Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 12:50 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–183 of 183 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Anti-TNF Clear all

Conditions: Crohn Disease
Interventions: UVADEX and UVAR XTS Photopheresis System; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Crohn's Disease
Interventions: Certolizumab Pegol (CDP870); Biological
Lead sponsor: UCB Pharma SA; Industry
Eligibility: 18 Years and older
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 41
States / cities: Birmingham, Alabama • Huntsville, Alabama • Little Rock, Arkansas + 37 more

Conditions: Rheumatoid Arthritis
Interventions: PF-05280586, MabThera, Rituxan; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 43
States / cities: Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 32 more

Conditions: Acquired Immunodeficiency Syndrome, HIV Infection
Interventions: IL-2 plus Anti-TNF or Thalidomide; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Rheumatoid Arthritis
Interventions: tofacitinib, tumor necrosis factor inhibitors (TNFi), abatacept, tocilizumab or sarilumab; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 21,340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Rheumatoid Arthritis
Interventions: Adalimumab, Placebo; Biological · Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 619 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2010
U.S. locations: 76
States / cities: Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 64 more

Conditions: Psoriasis
Interventions: etanercept; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Mycobacterium Avium-Intracellulare Infection, HIV Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 11
States / cities: San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 7 more

Conditions: Crohn's Disease, Ultrasound, Intestinal Fibrosis, Shear Wave Imaging, Acoustic Radiation Force Impulse
Interventions: Ultrasound stiffness imaging; Procedure
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Crohn's Disease
Interventions: PF-04236921 SC injection; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 98
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 45 more

Conditions: Tuberculosis, Pulmonary
Interventions: Azacitidine Injection; Drug
Lead sponsor: Andrew Dinardo; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Arthritis, Juvenile Idiopathic
Interventions: Double-Blind Adalimumab/Placebo + MTX, Double-Blind Adalimumab/Placebo, OLE BSA Adalimumab +/- MTX, OLE FD Adalimumab +/- MTX; Biological · Drug
Lead sponsor: Abbott; Industry
Eligibility: 4 Years to 17 Years
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2010
U.S. locations: 15
States / cities: Birmingham, Alabama • Los Angeles, California • Stanford, California + 12 more

Conditions: Rheumatoid Arthritis
Interventions: CDP6038, Tocilizumab (Actemra or RoActemra), Placebo sc, Placebo iv; Biological · Other
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 74
States / cities: Mesa, Arizona • Paradise Valley, Arizona • Scottsdale, Arizona + 66 more

Conditions: Rheumatoid Arthritis
Interventions: Indocyanine green, MultiSpectral Imaging System; Drug · Device
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Herpes Zoster, Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
Interventions: Not listed
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 35 Years to 49 Years
Enrollment: 97 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Madison, Wisconsin

Search by objective public record fields.

Extracorporeal Photopheresis to Maintain Symptoms Remission During Steroid Withdrawal in Patients With Steroid-Dependent Crohn's Disease

A follow-on Safety Study in Subjects With Crohn's Disease Who Have Previously Been Withdrawn From the Double-blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Due to an Exacerbation of Crohn's Disease

A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)

Home Treatment of HIV-Infected Patients With Interleukin-2 With or Without a Tumor Necrosis Factor Antagonist

A Study to Understand How Effective is Tofacitinib When Compared to Other Advanced Treatments in Patients With Rheumatoid Arthritis

Efficacy and Safety of Adalimumab in Patients With Active Rheumatoid Arthritis Treated Concomitantly With Methotrexate.

The Immunological Basis for Treatment Resistance to Anti-TNF Treatments

The Effects of Treatment for Mycobacterium Avium Complex (MAC) on the Cells of HIV-Infected Patients

Ultrasound Stiffness Imaging in Crohn's Disease

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Azacytidine During Anti-tuberculosis Therapy

Study of Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis (JIA)

Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy

Imaging of Lymphatic Vessels in People With Rheumatoid Arthritis (RA)

Identifying Young Inflammatory Bowel Disease Patients at Risk for Herpes Zoster